Fresh analysis indicates that patients who come off blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds far faster than those who stop traditional lifestyle programs.
Findings released in a leading medical journal points out that while obese people often shed substantial amounts of their body weight while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying such drugs need to be cognizant of the potential of rapid rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of regain implies a reversion to pre-treatment weight in about one and a half years.
Analyzing Treatments
The study, which looked at 37 of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with conventional dieting.
Researchers note that individuals who lose weight through diet and exercise typically see a slower creep back—around 100 grams monthly—post-intervention.
The Reason for the Rapid Rebound
Doctors believe the mechanism of the drugs is key to understanding the amplified rebound.
These medications mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels far above than normal could lead to the system to produce less of its endogenous GLP-1, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication means appetite is uncontrolled, making binge eating a significant risk."
A Chronic Issue?
Health authorities suggest the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
A number of clinicians contend that, due to the significant potential of weight regain, the therapy should be considered ongoing.
This perspective is supported by drug manufacturers, who say that the findings "highlight the chronic character of excess weight," akin to managing diseases like high blood pressure.
Patient Accounts
Individuals who have stopped the medication report a sudden resurgence of hunger.
"It felt as if a trigger that goes on and I was suddenly starving," recalled one woman.
This difficulty is compounded if users have not established permanent dietary or behavioural changes during treatment.
Significant Adoption
Survey data indicate that millions of adults in the UK have tried these injections in the past year, with interest being substantial.
- Use is higher among females than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, experts emphasize that while these medications are potent tools for weight loss, they are not a permanent cure and lasting health benefits hinges on integrated behavioural support.
